Melissa Ann Geller MD

Obstetrics & Gynecology•Minneapolis, MN

Gynecologic Oncology

Professor, Obstetrics & Gynecology, University of Minnesota Medical School Division of Gynecologic Oncology

Telehealth Available

Request Appointment

500 Harvard Street SEMinneapolis, MN 55455
Book by Phone+1(229) 490-4067

Education & Training

University of MinnesotaResidency, Obstetrics and Gynecology, 1998 - 2002
Chicago Medical School at Rosalind Franklin University of Medicine and ScienceClass of 1998

Certifications & Licensure

MN State Medical License 2002 - 2025
WI State Medical License 2023 - 2025
American Board of Obstetrics and Gynecology Obstetrics & Gynecology
American Board of Obstetrics and Gynecology Gynecologic Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Fellow (FACOG) American Congress of Obstetricians and Gynecologists

Clinical Trials

Carboplatin, Docetaxel, and Radiation Therapy in Treating Patients With Stage III/IV, or Recurrent Endometrial Cancer Start of enrollment: 2005 Jul 01
Completed
Phase 2
Study of Immune Response Modifier in the Treatment of Breast, Ovarian, Endometrial and Cervical Cancers Start of enrollment: 2006 Apr 01
Completed
Phase 2
Carboplatin, Paclitaxel, and Surgery in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer Start of enrollment: 2005 Oct 01
Terminated
Phase 2
Effect of Serotonin Level on Constipation Caused by Chemotherapy in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2007 Apr 01
Terminated
Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal Cancer Start of enrollment: 2008 Mar 01
Terminated
Phase 2
Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer Start of enrollment: 2010 Jul 01
Completed
Phase 2
Interactive Educational Website for Women With Ovarian Cancer & Caregivers Start of enrollment: 2012 Aug 01
Completed
Early Phase 1
Epacadostat Before Surgery in Treating Patients With Newly Diagnosed Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2014 Aug 25
COMPLETED
EARLY_PHASE1
Virexxa (Sodium Cridanimod) w/Progestin Therapy in Pts w/Progesterone Receptor Neg Recurrent/Persistent Endometrial CA Start of enrollment: 2014 Sep 01
Unknown status
Phase 2
Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Start of enrollment: 2014 Jul 28
Completed
Phase 1
IP ALT-803 Followed by SQ ALT-803 for Ovarian Cancer Start of enrollment: 2017 Sep 19
Completed
Phase 2
HCW9218 in Select Advanced Solid Tumors Start of enrollment: 2022 Apr 01
ACTIVE_NOT_RECRUITING
PHASE1
Roles: Principal Investigator, Contact
MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Start of enrollment: 2023 Apr 28
TERMINATED
PHASE1
Roles: Contact
Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Start of enrollment: 2024 Jul 11
RECRUITING
PHASE1
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Prospective assessment of prognostic significance of malignant peritoneal cytology in endometrial cancer: An NRG Oncology / Gynecologic Oncology Group study on GOG-210...
Koji Matsuo, Danielle M Enserro, Jason D Wright, Lynda D Roman, Matthew A Powell
Gynecologic Oncology. 2025-09-03
Novel trispecific killer engager targeting B7-H3 enhances natural killer cell antitumor activity against head and neck cancer.
Melissa J Khaw, Nicholas A Zorko, Philippa R Kennedy, Laura E Bendzick, Madison Shackelford
Journal for Immunotherapy of Cancer. 2025-07-23
(c.1100C) Genotype Is Associated with Distinct Tumoral and Clinical Outcomes in Breast and Endometrial Cancers.
Nikitha Vobugari, Allison Makovec, Samuel Kellen, Shayan S Nazari, Andrew Elliott
International Journal of Molecular Sciences. 2025-06-14

Press Mentions

HCW Biologics : Masonic Cancer Center at the University of Minnesota Receives FDA Clearance to Proceed with Phase 1 Clinical Trial in Solid Tumors for HCW9218, HCW Biologics' Novel Bifunctional Fusion Protein - Form 8-KJanuary 26th, 2022
The High Difficulty of Diagnosing Ovarian CancerDecember 1st, 2015
MOCA Fundraising Fuels 'U' Ovarian Cancer ResearchNovember 30th, 2015

Insurance Accepted

Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
BCBS Illinois PPO
BCBS Minnesota Blue Cross Accord
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
First Health PPO
GHI PPO
Great West PPO
HIP of New York - Select PPO
Humana ChoiceCare Network PPO
MagnaCare PPO
Multiplan PHCS PPO
Multiplan PPO
Oxford Health Freedom
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
WEA Trust Preferred Provider Plan - Trust Pref
Please verify your coverage with the provider's office directly when scheduling an appointment